| Volume: | 8,652,950 |
|---|---|
| Day's Low: | $45.40 |
| 52-wk Low: | $39.37 |
| Previous Close: | $45.50 |
| Dividend: | $0.00 |
| Market Cap: | 41,831,100 |
| Avg Volume: | 7,632,100 |
|---|---|
| Day's High: | $46.61 |
| 52-wk High: | $53.28 |
| Open Price: | $45.49 |
| Yield: | 0.00% |
| P/E (Forward): | 16.70 |
| 6:19 PM | 10/20/2009 | 2nd UPDATE: Gilead 3Q Net Rises 36%; Benefits From Tamiflu |
| 5:46 PM | 10/20/2009 | UPDATE: Gilead 3Q Net Rises 36%; Benefits From Tamiflu |
| 5:33 PM | 10/20/2009 | US EARNINGS WRAP: Yahoo, Sallie Mae Smash Profit Views |
| 4:40 PM | 10/20/2009 | Gilead 3Q Profit Rises 36% On Sales Growth, Results Beat Views |
| 2:40 PM | 10/16/2009 | US EQUITIES WEEK AHEAD: More 3Q Results; Windows 7 Launches |
| 11/5/2009 | Gilead (GILD): New potential in 4-in-1 HIV drug |
| 11/2/2009 | Turnaround Letter not for faint of heart |
| 10/26/2009 | J&J CEO's Lower-Risk Alternative to Acquisitions |
| 10/23/2009 | Two Top Ideas in Biotech |
| 10/20/2009 | SanDisk, Yahoo shares surge after results |
| 10/20/2009 | Updates, advisories and surprises |
| 10/20/2009 | Gilead's earnings jump on strong drug sales |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.74 | 0.52 | 42.31 |
| EPS, GAAP | 0.72 | 0.52 | 38.46 |
| Consensus Estimate | 0.69 | 0.50 | 38.00 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 2.62 | 2.11 | 24.17 |
| EPS, GAAP | 2.36 | 1.91 | 23.56 |
| Consensus Estimate | 2.46 | NA | NA |
| GILD | Industry Average | |
| P/E (TTM) | 19.60 | 185.00 |
| P/E (Forward) | 16.70 | -21.30 |
| PEG Ratio | 1.06 | -1.08 |
| Price/Sales | 7.23 | 4.67 |
| Beta | 0.45 | 0.39 |